Organogenesis’ (ORGO) Sell (D-) Rating Reiterated at Weiss Ratings

Organogenesis (NASDAQ:ORGO)‘s stock had its “sell (d-)” rating restated by investment analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

Several other analysts have also issued reports on the stock. BTIG Research restated a “buy” rating and issued a $7.00 price target on shares of Organogenesis in a research report on Friday, September 26th. Cantor Fitzgerald lifted their target price on Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Organogenesis presently has an average rating of “Hold” and an average price target of $7.33.

Organogenesis Stock Up 3.6%

Shares of NASDAQ ORGO opened at $4.26 on Friday. Organogenesis has a 12 month low of $2.61 and a 12 month high of $6.71. The company has a market cap of $540.42 million, a P/E ratio of -30.43 and a beta of 1.68. The business’s 50 day moving average is $4.53 and its two-hundred day moving average is $4.18.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. The business had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Sell-side analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ORGO. First Light Asset Management LLC bought a new position in Organogenesis during the second quarter worth about $24,804,000. Assenagon Asset Management S.A. raised its holdings in shares of Organogenesis by 69.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company’s stock worth $20,488,000 after buying an additional 1,997,038 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Organogenesis by 23.4% during the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after buying an additional 841,618 shares during the period. Acadian Asset Management LLC boosted its stake in Organogenesis by 3.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company’s stock valued at $8,862,000 after buying an additional 91,118 shares in the last quarter. Finally, Driehaus Capital Management LLC acquired a new stake in Organogenesis in the 1st quarter valued at $7,756,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.